Stereotaxis (STXS) CFO awarded 40,000 options at $1.87 strike price

Rhea-AI Filing Summary

Stereotaxis, Inc. Chief Financial Officer Kimberly R. Peery received a grant of stock options for 40,000 shares of common stock. The options carry an exercise price of $1.87 per share and expire on April 11, 2036, functioning as compensation rather than an open‑market purchase.

According to the vesting terms, 25% of the options vest one year after the grant date, with the remaining 75% vesting monthly over the next three years. Following this grant, Peery directly holds 340,750 derivative securities in total.

Insights

Equity Compensation Analyst

CFO receives time‑vested options grant as routine equity compensation.

The filing shows Kimberly R. Peery, CFO of Stereotaxis, Inc., receiving stock options for 40,000 shares at an exercise price of $1.87 per share, expiring on April 11, 2036. The grant price and long maturity align with typical executive incentive structures.

The vesting schedule is service-based: 25% after one year, then the remaining 75% vesting monthly over three years. This design encourages multi‑year retention and alignment with shareholders but does not represent an open‑market buy or sell decision.

After this grant, Peery holds 340,750 derivative securities directly. The transaction is categorized as a grant or award acquisition, a common component of executive pay, with no immediate cash outlay and no direct signal about short‑term views on the stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Peery Kimberly R.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options -Right to Buy	40,000	$0.00	--

Holdings After Transaction: Stock Options -Right to Buy — 340,750 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 40,000 options Exercise price: $1.87 per share Expiration date: April 11, 2036 +3 more

6 metrics

Option grant size 40,000 options Stock options for common stock granted to CFO

Exercise price $1.87 per share Strike price of newly granted options

Expiration date April 11, 2036 Option grant term to expiration

Post‑grant derivative holdings 340,750 derivative securities Total held directly after transaction

Initial vesting tranche 25% after one year First portion of options to vest

Remaining vesting 75% monthly over three years Balance of options vesting schedule

Key Terms

Stock Options, exercise price, derivative securities, Grant, award, or other acquisition, +1 more

5 terms

Stock Options financial

"The options vest as follows: (1) 25% vest one year after the date of grant"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"conversion_or_exercise_price": "1.8700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative securities financial

"derivativeTransactionCount": 1"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

vest financial

"25% vest one year after the date of grant, and (2) the remaining 75% vest ratably"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peery Kimberly R.

(Last) (First) (Middle)

C/O STEREOTAXIS, INC.

710 NORTH TUCKER BLVD.; SUITE 110

(Street)

ST. LOUIS MISSOURI 63101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stereotaxis, Inc. [ STXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options -Right to Buy	$1.87	04/11/2026		A		40,000		04/11/2027(1)	04/11/2036	Common Stock	40,000	$0	340,750	D

Explanation of Responses:

1. The options vest as follows: (1) 25% vest one year after the date of grant, and (2) the remaining 75% vest ratably per month over the next three years.

	/s/ Kimberly R. Peery	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Stereotaxis (STXS) disclose about CFO Kimberly Peery’s latest equity grant?

Stereotaxis disclosed that CFO Kimberly R. Peery received a grant of stock options for 40,000 shares of common stock at a $1.87 exercise price, expiring April 11, 2036. This is classified as a grant or award acquisition, not an open‑market stock purchase or sale.

What is the vesting schedule for Kimberly Peery’s 40,000 Stereotaxis (STXS) stock options?

The options vest 25% one year after the grant date, with the remaining 75% vesting ratably per month over the next three years. This time‑based vesting structure rewards continued employment and aligns Peery’s long‑term incentives with Stereotaxis shareholders’ interests.

What is the exercise price and expiration date of the new Stereotaxis (STXS) CFO options grant?

The stock options granted to CFO Kimberly Peery have an exercise price of $1.87 per share and expire on April 11, 2036. These terms give her a long‑dated opportunity to benefit from potential appreciation in Stereotaxis’ common stock over the coming years.

How many derivative securities does Stereotaxis (STXS) CFO hold after this Form 4 transaction?

Following the 40,000‑share stock option grant, CFO Kimberly Peery directly holds a total of 340,750 derivative securities. This figure reflects her post‑transaction option holdings reported in the Form 4 and helps indicate the scale of her equity‑based compensation exposure.

Does the Stereotaxis (STXS) Form 4 show the CFO buying or selling common stock in the market?

No. The Form 4 reports a grant of stock options to CFO Kimberly Peery, categorized as a grant or award acquisition with code A. It does not disclose any open‑market purchases or sales of Stereotaxis common stock by the CFO in this transaction.